Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Open Targets, Wellcome Genome Campus, Hinxton, UK; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK.
Open Targets, Wellcome Genome Campus, Hinxton, UK; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK.
Open Targets, Wellcome Genome Campus, Hinxton, UK; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK.
Open Targets, Wellcome Genome Campus, Hinxton, UK; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK.
Open Targets, Wellcome Genome Campus, Hinxton, UK; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK.
Human genetic evidence has been reported as a proxy for the success of drugs in clinical trials owing to its ability to pinpoint causal mechanistic links between drug targets and diseases. Two-thirds of the new drugs approved by the FDA in 2021 were supported by human genetic evidence associating the intended pharmacological target or its physical interactors with the indication or a surrogate trait. Here, we expand this retrospective analysis to FDA approvals from 2013–2022 (see Supplementary information for details). This analysis shows that currently available genetic evidence supported 63% (271 out of 428) of the new drugs approved in the past decade overall, with a range of 41–72% annually (Fig. 1). Approved drugs without obvious genetic support were often symptomatic treatments or molecules not targeting human gene products.